ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck Kgaa (OP:MKGAF)

149.36 -2.59 (-1.70%)

Streaming Delayed Price Updated: 1:08 PM EDT, Sep 11, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,621
Open	159.05
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	151.95
Today's Range	149.36 - 159.13
52wk Range	116.68 - 175.56
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Invo Fertility Stock Is Plunging After White House Announcement ↗

October 17, 2025

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.

Via Benzinga

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Via Benzinga

Performance

YTD	+3.4%	+3.4%
1 Month	-8.6%	-8.6%
3 Month	-7.3%	-7.3%
6 Month	+19.6%	+19.6%
1 Year	+16.3%	+16.3%

More News

EMD Serono, CVS Health To Partner On TrumpRx Fertility Program Launching In 2026 ↗

October 17, 2025

Via Benzinga

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗

September 26, 2025

Via The Motley Fool

Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts ↗

August 11, 2025

Via Benzinga

Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support

July 22, 2025

From Crown Bioscience

Via JCN Newswire

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Via Benzinga

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics ↗

February 11, 2025

Via Benzinga

GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗

January 13, 2025

Via Benzinga

Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED ↗

August 17, 2024

Via Talk Markets

Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗

December 06, 2023

Via Benzinga

Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion ↗

November 04, 2023

Via Talk Markets

Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors ↗

September 26, 2023

Via Benzinga

Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 ↗

August 03, 2023

Via Benzinga

Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗

July 26, 2023

Via Benzinga

Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation ↗

June 20, 2023

Via Benzinga

Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗

May 17, 2023

Via Benzinga

Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions ↗

April 18, 2023

Via Benzinga

FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study ↗

April 12, 2023

Via Benzinga

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer ↗

March 27, 2023

Via Benzinga

Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗

March 23, 2023

Via Benzinga

PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment ↗

January 03, 2023

Via Benzinga

Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗

December 23, 2022

Via Benzinga

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact ↗

September 30, 2021

Via Benzinga

Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study ↗

September 21, 2021

Via Benzinga

Frequently Asked Questions

Is Merck Kgaa publicly traded?

Yes, Merck Kgaa is publicly traded.

What exchange does Merck Kgaa trade on?

Merck Kgaa trades on the OTC Traded

What is the ticker symbol for Merck Kgaa?

The ticker symbol for Merck Kgaa is MKGAF on the OTC Traded

What is the current price of Merck Kgaa?

The current price of Merck Kgaa is 149.36

When was Merck Kgaa last traded?

The last trade of Merck Kgaa was at 09/11/26 01:08 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.